Formerly dba as Synthetic Genomics Inc., Viridos is a synthetic biology company developing and commercializing genomic-driven technologies for various industries. Focused on key commercialization programs, the firm is working on developing new synthetic DNA products, tools, and instruments; and vaccines and therapeutics, food and nutritional products, humanized organs for transplant, biofuels, bio based-chemicals, and agricultural solutions. The firm also produces algae based products, and human and animal nutrition products. Recently, management announced that it has extended its agreement on joint research into advanced algae biofuels after making significant progress in understanding algae genetics, growth characteristics and increasing oil production. Key players of major note in the firm specifically in the role of co-Scientific Officers of the firm are J Craig Venter recognized as one of the leading genomic research scientists, responsible most notably for the first sequencing and analysis of the human genome published in 2001 and the most complete sequencing of the diploid human genome in 2007 and Hamilton O Smith who in 1978 was co-recipient of the Nobel Prize in Physiology and Medicine for the discovery of Type II restriction enzymes, which led to the development of recombinant DNA technology and for his work on the discovery of restriction enzymes, essential tools used in the field of recombinant DNA technology.
